Stereotaxis Announces Acceptance into NVIDIA Connect Program and Highlights at NVIDIA GTC Conference

Stereotaxis announced NVIDIA's support and inclusion in its NVIDIA Connect program, highlighting advancements in robotic surgery and AI integration.

Quiver AI Summary

Stereotaxis, a leader in surgical robotics for minimally invasive endovascular interventions, announced that its technology was highlighted at the NVIDIA GPU Technology Conference (GTC) and that it has been accepted into the NVIDIA Connect program. NVIDIA's Vice President of Healthcare emphasized Stereotaxis' surgical robots and their integration of artificial intelligence (AI) at the event, which attracted over 25,000 attendees. Stereotaxis' robotic systems, used in over 100 leading hospitals worldwide, aim to advance minimally invasive surgeries and improve patient care. The company is focusing on enhancing its robotic technologies with digital solutions, AI, and decision support capabilities. CEO David Fischel expressed gratitude for NVIDIA's support, underscoring the transformative potential of combining robotics with AI innovations in patient treatment.

Potential Positives

• NVIDIA, a leading technology company, has highlighted Stereotaxis’ surgical robots at the NVIDIA GTC, which enhances the company's visibility and credibility in the medical technology field.
• Stereotaxis has been accepted into the NVIDIA Connect program, gaining access to advanced software development resources that can support its innovation efforts.
• The collaboration with NVIDIA signifies a strong commitment to integrating AI into Stereotaxis' technology, which could lead to significant advancements in endovascular robotic surgery.
• Stereotaxis' technology has a proven track record, having been used in over 100 hospitals globally to treat over 150,000 patients, demonstrating its impact and potential in the healthcare market.

Potential Negatives

• The press release includes extensive forward-looking statements that highlight numerous risks and uncertainties, indicating potential challenges in achieving future business goals.
• There is no specific information provided about the financial performance or growth metrics of Stereotaxis, which may raise concerns among investors regarding the company's current market position.
• The mention of dependencies on third-party vendors and the uncertainty around regulatory approvals could create doubts about the company's operational stability and market acceptance.

FAQ

What recent recognition did Stereotaxis receive from NVIDIA?

Stereotaxis was highlighted at NVIDIA GTC and accepted into the NVIDIA Connect program, showcasing its surgical robotics technology.

How has Stereotaxis impacted patient care globally?

Stereotaxis' robotic technologies have been used to treat over 150,000 patients across more than 100 leading hospitals worldwide.

What is the focus of Stereotaxis for future innovations?

Stereotaxis aims to enhance its robotic systems with digital solutions, AI, and robotic automation for improved surgical interventions.

Who is the chairman of Stereotaxis?

David Fischel serves as the Chairman and CEO of Stereotaxis, emphasizing the company's commitment to advancing robotics in healthcare.

Where can I find more information about Stereotaxis?

More information about Stereotaxis and its innovations can be found on their official website at www.stereotaxis.com.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$STXS Insider Trading Activity

$STXS insiders have traded $STXS stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $STXS stock by insiders over the last 6 months:

• PAUL J ISAAC has made 3 purchases buying 62,788 shares for an estimated $113,616 and 0 sales.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$STXS Hedge Fund Activity

We have seen 44 institutional investors add shares of $STXS stock to their portfolio, and 28 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• VANGUARD GROUP INC added 382,412 shares (+12.4%) to their portfolio in Q4 2024, for an estimated $871,899
• REDMILE GROUP, LLC removed 308,754 shares (-14.6%) from their portfolio in Q4 2024, for an estimated $703,959
• LAGODA INVESTMENT MANAGEMENT, L.P. added 295,700 shares (+7.7%) to their portfolio in Q4 2024, for an estimated $674,196
• ESSEX INVESTMENT MANAGEMENT CO LLC removed 197,165 shares (-14.0%) from their portfolio in Q4 2024, for an estimated $449,536
• TRAYNOR CAPITAL MANAGEMENT, INC. added 160,509 shares (+inf%) to their portfolio in Q4 2024, for an estimated $365,960
• GOLDMAN SACHS GROUP INC added 152,056 shares (+154.3%) to their portfolio in Q4 2024, for an estimated $346,687
• WARBERG ASSET MANAGEMENT LLC removed 144,860 shares (-71.5%) from their portfolio in Q4 2024, for an estimated $330,280

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Full Release

ST. LOUIS, March 19, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that NVIDIA highlighted Stereotaxis’ technology at NVIDIA GTC and has accepted Stereotaxis into the NVIDIA Connect program.

NVIDIA GTC (GPU Technology Conference) is a global artificial intelligence (AI) conference that brings together engineers, researchers, and inventors working to pioneer applications for AI. This year’s conference has brought together over 25,000 attendees in San Jose this week. At a special address by NVIDIA’s Vice President of Healthcare and Life Sciences, NVIDIA highlighted Stereotaxis’ surgical robots and the efforts to incorporate AI into robotics heralding a new chapter in medical progress. NVIDIA also recently accepted Stereotaxis into its NVIDIA Connect program, which supports member companies with NVIDIA’s software development resources, industry-leading frameworks and software development kits.

Stereotaxis’ robotic technologies are at the forefront of efforts to advance robotics in minimally-invasive endovascular surgeries. Its robots have already been used by physicians at over 100 leading hospitals globally to treat over 150,000 patients. As Stereotaxis nears completion of its initial wave of core innovations in robotics and interventional devices, it has set its sights on the next phase of technological progress. This includes a pronounced focus on digital solutions that enhance its robotic systems and the operating room environment with artificial intelligence, robotic automation, data integration and decision support capabilities. Stereotaxis has already begun meaningful investments in these efforts.

“We greatly appreciate the support of NVIDIA in our efforts to pioneer endovascular robotics and take the technology to new incredible heights,” said David Fischel, Stereotaxis Chairman & CEO. “The combination of robotics’ mechanistic benefits – precision, safety, stability – with the promise of AI innovations will dramatically transform what is possible in treating patients. We are excited for the path ahead of us.”

About Stereotaxis




Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit


www.stereotaxis.com


.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.

Stereotaxis Contacts:




David L. Fischel


Chairman and Chief Executive Officer

Kimberly Peery


Chief Financial Officer

314-678-6100


Investors@Stereotaxis.com

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.